Replies to post #391441 on Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

My comment was regarding the fact that you can’t look at the $2M as a benefit in a bubble. There was a significant aspect that was missing from a fair look. Blame it on FDA/gov all you want. Nasrat doesn’t get a free pass.

For me, it’s in the past. I’m more interested in diversifying away from CNS/opioids in case something happens here. Too much concentration. Solid growth, I’m excited. Many fumbles along the way and yet we’re finally in the growth stretch. I’m beyond content.